Thomas Westbrook, MD
Allergy & Immunology · Pensacola, FLNPI 1396716775
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $647,735 of the $809,604 with a category attached, or 80.0%. 41 manufacturers reported payments, led by AstraZeneca at 44.1% of the total. Reporting peaked in 2024 at $177,448 and has fallen 54.9% since, to $80,113 in 2025. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,903 payments — averaging $425.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$357K
- Regeneron Healthcare Solutions, Inc.$139K
- Pharming Healthcare, Inc.$90K
- GSK$66K
- Sanofi$63K
- Optinose US, Inc.$19K
- plus $76K from 35 others
Across 14 payments — averaging $8235.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$115K
- Novartis$96
What the payments were for
- Consulting fees$70,1779%
- Speaking & faculty fees$647,73580%
- Travel & lodging$47,0286%
- Food & beverage$44,1915%
- Education$4720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$192,824
- TEZSPIRE$165,798
- FASENRA$136,537
- RUCONEST$88,137
- AIRSUPRA$54,966
- TRELEGY ELLIPTA$34,200
- Xhance$17,537
- XOLAIR$15,088
- Andembry$6,344
- Hizentra$5,782
- Prolastin-C Liquid$5,523
- Ryaltris$5,008
- ProAir Digihaler$1,680
- ArmonAir Digihaler$1,680
- AirDuo RespiClick$1,680
- Zerviate$500
- BREZTRI$403
- Haegarda$378
- CINQAIR$316
- AYVAKIT$140
How this compares
$809,604 in reported general payments places this provider in the 95th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 13 | $535,337 |
| Dupixent PenDupilumab | 40 | $153,861 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 32 | $81,487 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $66,951 |
| Dupixent SyringeDupilumab | 15 | $62,976 |
| XolairOmalizumab | 13 | $50,124 |
| CutaquigImmun Glob G(Igg)-Hipp/Maltose | 32 | $46,734 |
| Spiriva RespimatTiotropium Bromide | 58 | $38,408 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $29,100 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,902 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $19,058 |
| XhanceFluticasone Propionate | 13 | $14,246 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $8,976 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,881 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $6,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $485 | $535,33713 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $66,108 | $99,310169 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $818 | $81,48732 claims |
| Octapharma USA, Inc.Cutaquig | $486 | $46,73432 claims |
| Boehringer IngelheimSpiriva Respimat | $3,294 | $38,40858 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $357,380 | $30,87766 claims |
| Grifols USA, LLCGamunex-C | $7,071 | $29,10011 claims |
| Optinose US, Inc.Xhance | $18,950 | $14,24613 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $5,075 | $6,88631 claims |
| MerckDulera | $33 | $5,87916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Pensacola
- Stephen KimuraPensacola$15K
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.